There are encouraging results from clinical trials with MEK inhibitors [50], and our data validates the therapeutic targeting of MEK or its upstream regulators (e.g. clinical trials of erlotinib) in bladder cancer [7], [51]. The gene discussed is MAP2K7; the disease is urinary bladder carcinoma.